

October 5th, 1972

Dr. Jerome Jaffe,
SAODAP,
The White House,
Washington, D.C.

Dear Jerry,

I am enclosing two preprints of reports that we have submitted to the American Psychiatric Association.

The levomethadyl study confirms our previous study and that of your co-workers that the effective 72 hour dose of levomethadyl is above 70 mg. We are impressed with both the safety and efficacy of levomethadyl and would like to undertake a more extensive clinical trial. In calling N.I.M.H. regarding additional supplies, I have been notified that the supplies are restricted, and plans for an extended clinical study are not an adequate justification for the release of the available supplies. I have also been told that the restrictions in studies are based on presumed FDA requirements for extended toxicology. Are we, in fact, restricted from extending a levomethadyl study to all the patients at Metropolitan Hospital?

The second report demonstrates that cyclazocine can be given in higher dosages with good tolerance development for agonistic effects. Our initial heroin challenges suggest an extension of antagonism to more than 48 hours, and should this be confirmed, we will undertake a three times a week delivery schedule.

(These two studies were done at the New York Medical College and will continue at that unit).

Good luck in your efforts!

Sincerely yours,

Max Fink, M.D.

MF/ij
Encs.